Provided by Tiger Fintech (Singapore) Pte. Ltd.

AstraZeneca PLC

77.50
+0.03000.04%
Pre-market: 76.25-1.2500-1.61%09:19 EDT
Volume:7.02M
Turnover:545.79M
Market Cap:240.34B
PE:34.44
High:78.25
Open:77.69
Low:77.28
Close:77.47
Loading ...

Ionis Pharmaceuticals Says Transthyretin-Mediated Amyloidosis Treatment Gets Approval in Europe

MT Newswires Live
·
1 hour ago

3 Top Cancer Biotechs to Keep An Eye On in 2025

Zacks
·
07 Mar

Astrazeneca Adjunctive Gastric Cancer Treatment Study Meets Primary Endpoint

MT Newswires Live
·
07 Mar

AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients

Benzinga
·
07 Mar

AstraZeneca announces MATTERHORN trial results

TIPRANKS
·
07 Mar

IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers

Business Wire
·
07 Mar

AstraZeneca’s MATTERHORN Phase III trial showed improvement in endpoint of EFS

TIPRANKS
·
07 Mar

Astrazeneca (AZN) Stock Moves -0.63%: What You Should Know

Zacks
·
07 Mar

Inside The Quantum Computing Crash Triggered By Nvidia CEO — And What His Upcoming 'Quantum Day' May Bring

Blockhead
·
06 Mar

Is AstraZeneca PLC (LON:AZN) Trading At A 45% Discount?

Simply Wall St.
·
06 Mar

AstraZeneca PLC Stock Falls Wednesday, Underperforms Market

Dow Jones
·
06 Mar

Compugen Ltd (CGEN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

GuruFocus.com
·
05 Mar

AstraZeneca PLC ADR Outperforms Competitors On Strong Trading Day

Dow Jones
·
05 Mar

AstraZeneca (AZN) Receives a Buy from Bernstein

TIPRANKS
·
04 Mar

AstraZeneca PLC Stock Falls Monday, Underperforms Market

Dow Jones
·
04 Mar

Astrazeneca-Amgen Asthma Treatment Reduces Nasal Polyps, Surgery Rates in Phase III Trial

MT Newswires Live
·
03 Mar